about
Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plantsPatterns of CRISPR/Cas9 activity in plants, animals and microbesThe contribution of transgenic plants to better health through improved nutrition: opportunities and constraintsCombinatorial genetic transformation of cereals and the creation of metabolic libraries for the carotenoid pathway.Molecular farming in plants: host systems and expression technology.Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.Techniques patents for SNP genotyping.Production of antibodies in plants and their use for global health.Molecular and ultrastructural analysis of forisome subunits reveals the principles of forisome assembly.Transgene integration, organization and interaction in plants.Plant-based production of biopharmaceuticals.SNP discovery and typing technologies for pharmacogenomics.Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment.Transgenic plants in the biopharmaceutical market.Plant-derived pharmaceuticals--the road forward.The potential of plant virus vectors for vaccine production.The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter NanorodsEvolution of a regulatory framework for pharmaceuticals derived from genetically modified plants.The distribution of carotenoids in hens fed on biofortified maize is influenced by feed composition, absorption, resource allocation and storage.Promoter diversity in multigene transformation.Nutritionally enhanced crops and food security: scientific achievements versus political expediency.Bacillus thuringiensis: a century of research, development and commercial applications.GMP issues for recombinant plant-derived pharmaceutical proteins.Nutritious crops producing multiple carotenoids--a metabolic balancing act.The use of plants for the production of therapeutic human peptides.Field trials and tribulations--making sense of the regulations for experimental field trials of transgenic crops in Europe.Optimizing the yield of recombinant pharmaceutical proteins in plants.Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures.Paradoxical EU agricultural policies on genetically engineered crops.A question of balance: achieving appropriate nutrient levels in biofortified staple crops.Engineering metabolic pathways in plants by multigene transformation.Strategic patent analysis in plant biotechnology: terpenoid indole alkaloid metabolic engineering as a case study.Can plant biotechnology help break the HIV-malaria link?The characteristics and potential applications of structural lipid droplet proteins in plants.Knowledge-driven approaches for engineering complex metabolic pathways in plants.High-value products from plants: the challenges of process optimization.Insects as models to study the epigenetic basis of disease.Extraction and downstream processing of plant-derived recombinant proteins.Virus-based nanoparticles as platform technologies for modern vaccines.Antibodies from plants for bionanomaterials.
P50
Q24539099-940D3957-ACC8-4089-A79A-121109BA6509Q28078150-66811DAB-1589-4A0A-BD6F-0809EB2CDF09Q28710129-CCED5BED-B41B-4505-BD17-045554653AE6Q34164901-20921617-FBE7-4E8A-9D8E-D9A2C02B851CQ34277628-EFFC98CF-589F-4398-90F2-66DC48C2BB0CQ34652077-4248E76C-BCD2-49D0-B6B7-8EDDF0E2FD22Q35040891-118AEFE5-6142-418C-93CA-41179CC3CCC0Q35047030-521BA398-E6F5-461D-8002-0E6E4A02F3EAQ35138261-1CD148DD-9309-4BDD-AE64-7ED20EDAAF46Q35176030-16E935AA-79DF-4AEA-9DF0-9BF5493763A8Q35683387-C474D900-19DE-4299-AC5D-120351062570Q35892848-B0B47120-BA45-484C-9C6D-913B6981B622Q36055955-44D52DCE-E290-4CCE-A486-C784F65BDD49Q36066053-B38AC768-D70B-41FB-A74B-C07F88173529Q36313817-D04F166D-EFB6-46D7-88EB-FAD4A11A383DQ36511239-B956EB73-E3B1-459C-9487-7D8E6FCDD9C0Q37068238-855B919F-7275-413C-A15C-A0542C38B39CQ37233850-8F245B4C-50D9-476E-9D98-2D2877E42FE5Q37339809-E453B9F5-4A7A-4C0E-90B7-3F56DBFAD22FQ37721866-4D4B6619-F58F-4AD9-9C0A-74147FBB57DDQ37814679-4284F136-06AD-4BBF-B10E-30CEFDF866E7Q37849838-E9BFB104-239E-4906-8607-D7BC7F3F9844Q37920382-91B4976E-983B-47F6-A1B0-F056212D1F65Q37928799-44AAF29A-65F4-46AE-89BE-D4B8A610492CQ37973256-12AA811C-5642-426F-B668-835732511309Q37979439-9092AE39-CE54-4C94-B174-C098C7A759DFQ38080183-FD891C3A-7F8F-4C32-8F90-5F31EE501E24Q38080185-623FB163-CAEC-4E41-8DE7-45CD71991028Q38102400-1361A95A-1CDC-41B4-9816-A6493CA63948Q38153493-AFAEDBE2-05AE-4DF6-B06D-8F9DA19DB1C3Q38156086-573DCBED-5CB9-4197-8483-E84A923D2BABQ38181611-2CB54586-5050-4E43-B4AA-113ACBFBAB91Q38194350-92770A11-138F-4AD6-8571-341F321373EEQ38243729-8B5FD4B1-AD13-44CE-8F06-9152A71C58AEQ38275308-3AC88893-EB1B-4E8B-B78B-7DF1D84ABE3DQ38308799-DC5FAE80-4A4D-405B-A6F4-ECC3B6748003Q38380702-5FD78140-35AD-4FFE-A30D-ECF8D1C3DA7AQ38448207-5FD469A2-69B7-4E78-B5A3-729850D212B0Q38702017-6D3C98B3-95C3-4AA9-912C-2794513984E4Q38739385-32C3E4E6-E16B-42BB-9985-23C00BC2BA8B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard M. Twyman
@ast
Richard M. Twyman
@en
Richard M. Twyman
@es
Richard M. Twyman
@nl
Richard M. Twyman
@sl
type
label
Richard M. Twyman
@ast
Richard M. Twyman
@en
Richard M. Twyman
@es
Richard M. Twyman
@nl
Richard M. Twyman
@sl
prefLabel
Richard M. Twyman
@ast
Richard M. Twyman
@en
Richard M. Twyman
@es
Richard M. Twyman
@nl
Richard M. Twyman
@sl
P106
P1153
7006046916
P21
P31
P496
0000-0002-8764-3003